2021 Australian Pain Society Dr. Jeremy Henson

Date:  2021-04-27
Author:   Dr. Jeremy Henson
Can improved mucosal absorption allow a THC/CBD oro-buccal spray to achieve clinical efficacy in chronic pain?
Practitioner login to view

ABOUT THE AUTHOR

Dr. Jeremy Henson, Medical Affairs Director of Medlab
Medical Affairs Director
Dr. Jeremy Henson

Jeremy has 18 years’ experience in cancer research. He is the Principal Investigator of the Cancer Cell Immortality research group, UNSW Medicine, where his research involves the development of cancer treatments and diagnostics that target telomere maintenance mechanisms (telomerase and ALT). Jeremy discovered and patented the C-Circle biomarker and assay for the alternative-lengthening-of-telomeres (ALT) cancer mechanism (Nature Biotechnology, 2009) and is currently developing the C-Circle Assay as a cancer diagnostic and using it to perform a high-throughput screen for ALT inhibitors, which could be used as ALT-targeted cancer therapies. 

Jeremy is also Chief Career Medical officer at Lakeview Private Hospital, where he is a member of the Medical Advisory and Root Cause Analysis Committees, and a clinical tutor at Prince of Wales Clinical School, UNSW Faculty of Medicine. At Medlab, Jeremy's responsibilities include overseeing pharmacovigilance, research, clinical trials and new product development.